Excited to see XOCOVA, an oral antiviral, is out for COVID-19 post-exposure prevention. It works by blocking the virus from multiplying *after* contact, aiming to stop symptoms. Trials showed a 67% reduction in symptomatic cases. A really promising new approach.
Shionogi Announces U.S. Availability of XOCOVA® (ensitrelvir), the First and Only Oral Option to HelShionogi & Co., Ltd. has announced the availability of XOCOVA (ensitrelvir) in the U.S., an oral antiviral approved for post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 and oldewww.shionogi.com